



[Projectevolution.org](http://Projectevolution.org)

## SECOND HALF FEBRUARY 2023 ADVANCED THERAPIES PEOPLE MOVEMENTS

REACH OUT TO BRYAN KENNEDY AT [BK@PROJECTEVOLUTION.ORG](mailto:BK@PROJECTEVOLUTION.ORG) WITH ANY QUESTIONS

- 03.01.23 - Strand Therapeutics Appoints Jay Stella as Chief Business Officer (PR)
  - BOSTON—(BUSINESS WIRE)—Strand Therapeutics, the programmable mRNA company developing curative therapies for cancer and other diseases, today announced the appointment of Jay Stella, MBA as Chief Business Officer. He will establish and lead corporate and business development, and also be responsible for portfolio strategy, new product planning, and finance. Jay brings close to three decades of leadership in the pharmaceutical and biomedical industries with extensive experience in strategy, finance, and operations. Most recently, he was responsible for Corporate Strategy and Business Development at Akouos, Inc., a Boston-based precision genetic medicines company and played an instrumental role in the sale of the company to Eli Lilly. Jay has also worked for Sai Life Sciences, Takeda, Millennium, Biogen, Genetics Institute, as an independent consultant.
- 02.28.23 - Nationwide Children's spinoff Andelyn Biosciences promotes CEO from within ([bizjournal](#))
  - Wade Macedone was promoted to CEO after serving as COO since the biotech started building its Columbus facility in October 2020. Before that he led the gene therapy manufacturing operations that the hospital spun out to form the for-profit affiliate.
- 02.28.23 - Korro Bio Appoints Dr. Steve Colletti as Chief Scientific Officer (PR)
  - Korro Bio is a leading RNA editing company focused on the discovery and development of novel genetic medicines appointed Dr. Colletti CSO. He previously served as Senior Vice President of Drug Discovery R&D at Zymergen (acquired by Ginkgo Bioworks in 2022) and as Chief Scientific Officer at Lodo Therapeutics (acquired by Zymergen in 2021). He has over 24 years of experience at Merck, with leadership in drug discovery and development across multiple therapeutic areas. At Merck, Dr. Colletti built and led the RNA Therapeutics Medicinal Chemistry department in 2008, and he was a core member of multiple teams that were responsible for discovering over a dozen preclinical candidates and advancing them to clinical development.
- 02.27.23 - Cellipont Bioservices, a cell therapy CDMO announced two additions to its commercial leadership team. Brian Walsh joined the company as Senior Vice President, Business Development and Aaron Solis joined as Senior Director, Business Development. (PR)
  - [Brian Walsh](#) is an accomplished sales leader with a 25+ year track-record leading growth efforts across CRO/CDMO services and commercial products. Brian's experience spans drug discovery, development and manufacturing. Prior to joining Cellipont, Brian was Vice President of Business Development at Abzena, a fully integrated global biologics CDMO, where he significantly expanded the company's biologics CDMO services in the U.S. and Asia. Previously, he was Vice President of Business Development for Aptuit, an integrated discovery, development and manufacturing CRO/CDMO, where he was instrumental in rebranding their integrated services, significantly accelerating sales and revenues globally.
  - [Aaron Solis](#) brings nearly 15 years of experience in biotechnology and CDMO operations to Cellipont. He has held a range of operational and business roles at both Lonza and MaSTherCell (acquired by Catalent in 2020). Previously, he was a Tissue Engineer at Baylor College of Medicine's Cell and Gene Therapy Unit.
- 02.22.23 - Ansa Bio Appoints Dr. Matthew McManus as Chair of the Board
  - Dr. McManus brings decades of experience in the life sciences industry to the Board. He was most recently EVP and Chief Operating Officer at Azenta (NASDAQ:AZTA), a global life sciences tools, products, and services company. Prior to Azenta, Dr. McManus was Senior Vice President and General Manager of the Molecular Diagnostics Division at Bio-Techne following its acquisition of Asuragen, where he served as President and CEO and led the strategic transformation of the business into a profitable global molecular diagnostics company. Previously, Dr. McManus was the President and CEO of PrimeraDx, a company that developed and commercialized a novel molecular diagnostics instrument platform and was acquired by Qiagen. Ansa Biotechnologies is building a fast and reliable DNA synthesis service to accelerate synthetic biology research. Our core technology is a novel DNA synthesis method based on enzymes that is faster, cleaner, and more accurate than existing methods.
- 02.17.23 - Gilead's Shaw to step down from role running cell therapy unit ([biopharmadive](#))
  - Top Gilead Sciences executive Christi Shaw will leave the company at the end of March after more than three years running the drugmaker's Kite cell therapy division, Gilead announced Friday. Over that time, Shaw helped grow Kite into a leading producer of the complex medicines and an important contributor to Gilead's overall business, which has long been dominated by pills for HIV and hepatitis C. Last year, sales of the Gilead's two marketed cell therapies, approved to treat certain blood cancers, totaled nearly \$1.5 billion, or about 6% of the company's revenue outside of its COVID-19 drug Veklury. She's also overseen an expansion of Kite's manufacturing capabilities, which are critical for producing personalized cellular medicines. The kind of cell therapy Kite specializes in, known as CAR-T, requires immune cells to be extracted from each individual patient, reengineered in a laboratory to more effectively target cancer and then reinfused. The multi-week process involves careful managing of supply chains spanning states, countries and oceans. Gilead said Shaw will work with CEO Daniel O'Day and the Kite team to hand off her responsibilities while the company searches for her replacement.
- 02.16.23 - Vir Biotechnology Appoints Sung Lee as Chief Financial Officer (PR)
  - Mr. Lee is an experienced CFO who brings more than 20 years of finance leadership expertise in biopharmaceutical and technology businesses to Vir. He began his career in the tax advisory business at PwC, and later spent 14 years at Gilead Sciences, Inc., where he served in roles of increasing responsibility and scope, ultimately leading the Company's global financial planning and analysis, and investor relations functions. He has since served as CFO of Sangamo Therapeutics, Inc., and, most recently, served as CFO of MorphoSys AG. He received a Master of Business Taxation degree from the University of Southern California and a bachelor's degree in Economics from the University of California, Irvine.